High levels of LDL-C combined with low levels of HDL-C further increase platelet activation in hypercholesterolemic patients

High levels of low-density lipoprotein cholesterol (LDL-C) enhance platelet activation, whereas high levels of high-density lipoprotein cholesterol (HDL-C) exert a cardioprotective effect. However, the effects on platelet activation of high levels of LDL-C combined with low levels of HDL-C (HLC) have not yet been reported. We aimed to evaluate the platelet activation marker of HLC patients and investigate the antiplatelet effect of atorvastatin on this population. Forty-eight patients with high levels of LDL-C were enrolled. Among these, 23 had HLC and the other 25 had high levels of LDL-C combined with normal levels of HDL-C (HNC). A total of 35 normocholesterolemic (NOMC) volunteers were included as controls. Whole blood flow cytometry and platelet aggregation measurements were performed on all participants to detect the following platelet activation markers: CD62p (P-selectin), PAC-1 (GPIIb/IIIa), and maximal platelet aggregation (MPAG). A daily dose of 20 mg atorvastatin was administered to patients with high levels of LDL-C, and the above assessments were obtained at baseline and after 1 and 2 months of treatment. The expression of platelets CD62p and PAC-1 was increased in HNC patients compared to NOMC volunteers (P

低密度脂蛋白胆固醇（low-density lipoprotein cholesterol, LDL-C）水平升高可增强血小板活化，而高密度脂蛋白胆固醇（high-density lipoprotein cholesterol, HDL-C）水平升高则发挥心脏保护作用。但目前尚未见关于低密度脂蛋白胆固醇水平升高合并高密度脂蛋白胆固醇水平降低（HLC）对血小板活化影响的相关研究报道。本研究旨在评估HLC患者的血小板活化标志物，并探究阿托伐他汀对此类人群的抗血小板作用。本研究共纳入48例LDL-C水平升高的患者，其中23例为HLC患者，剩余25例为LDL-C水平升高合并高密度脂蛋白胆固醇水平正常（HNC）患者；另纳入35例胆固醇正常（NOMC）志愿者作为对照。所有受试者均接受全血流式细胞术检测及血小板聚集度测定，以检测下述血小板活化标志物：CD62p（P-选择素）、PAC-1（糖蛋白IIb/IIIa）以及最大血小板聚集率（MPAG）。为上述LDL-C水平升高的患者予以每日20 mg阿托伐他汀治疗，并于基线期、治疗1个月及2个月时完成上述检测评估。与NOMC志愿者相比，HNC患者的血小板CD62p及PAC-1表达水平升高（P